SynthesisPLoS neglected tropical diseases2019
Estimating the current burden of Chagas disease in Mexico: A systematic review and meta-analysis of epidemiological surveys from 2006 to 2017.
Synthesis in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic diversity and geographical distribution of Trypanosoma cruzi DTUs in Mexico: A Systematic Review.Revista da Sociedade Brasileira de Medicina Tropical · 2026Pooled it
- Noninvasive Biological Samples to Detect and Diagnose Infections due to Trypanosomatidae Parasites: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- The 2026 Men's FIFA Football World Cup: Evidence-Based Guidelines to Protect Player Health and Performance from Environmental Challenges.Sports medicine (Auckland, N.Z.) · 2026Review
- Amides from Porcelia ponderosa Roots Display Efficacy In Vitro Against Intracellular Amastigotes of Trypanosoma cruzi.Chemistry & biodiversity · 2026Article
- Successful control of Triatoma dimidiata with residual application of a microencapsulated formulation of pirimiphos-methyl (Actellic 300CS) in southeast Mexico.PLoS neglected tropical diseases · 2025Article
- Prenatal Chagas disease screening in Latin America: the current policy landscape and potential utility of an expanded maternal-familialLancet regional health. Americas · 2025Review
- MaxEnt modeling and risk evaluation of chagas disease vectors in the domestic cycle of Hidalgo, Mexico.PLoS neglected tropical diseases · 2025Article
- Prevalence, knowledge, attitudes, and practices regarding Chagas disease in Guanare, Venezuela: a cross-sectional study.Parasites & vectors · 2025Article
- Biological and Molecular Characterization of FiveTropical medicine and infectious disease · 2025Article
- Identification of seropositive cases of Chagas disease in pregnant women in a non-endemic risk area of the state of Mexico: The importance of screening prenatal.Parasite epidemiology and control · 2025Article
- (In)coherence between Chagas disease policy and the experiences of those affected in Mexico: The need for a transdisciplinary approach.PLoS neglected tropical diseases · 2025Article
- Serological determination of Trypanosoma cruzi in northern region of the State of Mexico.Parasitology research · 2025Article
- Expression Analysis of Thirteen Genes in Response to Nifurtimox and Benznidazole in Mexican Isolates of Trypanosoma cruzi by Digital PCR.Acta parasitologica · 2025Article
- Diagnosis of Trypanosoma cruzi infection in Mexican populations: current conventional serology lacks adequate sensitivity and specificity.Memorias do Instituto Oswaldo Cruz · 2025Article
- Glycosylation Patterns inMicroorganisms · 2025Article
- Presence of Trypanosoma cruzi (TcI) in different tissues of Didelphis virginiana from the metropolitan area of Merida, southeastern Mexico: Epidemiological relevance and implications for non-vector transmission routes.PLoS neglected tropical diseases · 2024Article
- Prevalence ofTropical medicine and infectious disease · 2024Article
- Tumor-Suppressive Cross-Linking of Anti-International journal of molecular sciences · 2024Article
- Prevalence and transmission of the most relevant zoonotic and vector-borne pathogens in the Yucatan peninsula: A review.PLoS neglected tropical diseases · 2024Review
- Seroprevalence of Trypanosoma cruzi among children from Veracruz, Mexico: Epidemiological baseline for a control model based on Chagas disease active transmissionBiomedica : revista del Instituto Nacional de Salud · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Mexico, estimates of Chagas disease prevalence and burden vary widely. Updating surveillance data is therefore an important priority to ensure that Chagas disease does not remain a barrier to the development of Mexico's most vulnerable populations. METHODOLOGY/PRINCIPAL
findingsThe aim of this systematic review and meta-analysis was to analyze the literature on epidemiological surveys to estimate Chagas disease prevalence and burden in Mexico, during the period 2006 to 2017. A total of 2,764 articles were screened and 36 were retained for the final analysis. Epidemiological surveys have been performed in most of Mexico, but with variable study scale and geographic coverage. Based on studies reporting confirmed cases (i.e. using at least 2 serological tests), and taking into account the differences in sample sizes, the national estimated seroprevalence of Trypanosoma cruzi infection was 3.38% [95%CI 2.59-4.16], suggesting that there are 4.06 million cases in Mexico. Studies focused on pregnant women, which may transmit the parasite to their newborn during pregnancy, reported an estimated seroprevalence of 2.21% [95%CI 1.46-2.96], suggesting that there are 50,675 births from T. cruzi infected pregnant women per year, and 3,193 cases of congenitally infected newborns per year. Children under 18 years had an estimated seropositivity rate of 1.51% [95%CI 0.77-2.25], which indicate ongoing transmission. Cases of T. cruzi infection in blood donors have also been reported in most states, with a national estimated seroprevalence of 0.55% [95%CI 0.43-0.66]. CONCLUSIONS/SIGNIFICANCE: Our analysis suggests a disease burden for T. cruzi infection higher than previously recognized, highlighting the urgency of establishing Chagas disease surveillance and control as a key national public health priority in Mexico, to ensure that it does not remain a major barrier to the economic and social development of the country's most vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.